Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)

Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward

Research output: Contribution to journalComment/debate

Abstract

The article “Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours”, written by Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward, was originally published electronically on the publisher’s internet portal on 18 November 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 2 December 2021 to

Original languageEnglish
Article number310
Pages (from-to)310
Number of pages1
JournalBritish Journal of Cancer
Volume126
Issue number2
DOIs
Publication statusPublished - 1 Feb 2022

Keywords

  • phase 1A/1B
  • dose-escalation
  • pamiparib
  • Solid tumor
  • pharmacokinetics
  • antitumor activity
  • adverse events

Fingerprint

Dive into the research topics of 'Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)'. Together they form a unique fingerprint.

Cite this